SecSonar.com

4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

4D Molecular Therapeutics, Inc. (FDMT) is a Biotechnology company based in US with a market capitalization of $506.6M. Revenue grew 230194.6% year-over-year and free cash flow was negative at -$109.6M. This page tracks FDMT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 227 employees · IPO Dec 11, 2020

Valuation

Valuation & price

$9.15 · as of May 17, 2026 · -31.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.00

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$12.95$8.45$3.95Jul 25Dec 25Jul 26Jul 7, 25$3.95Jul 9, 25$4.42Jul 11, 25$4.28Jul 15, 25$4.16Jul 17, 25$4.36Jul 21, 25$4.24Jul 23, 25$4.71Jul 25, 25$4.57Jul 29, 25$4.36Jul 31, 25$4.50Aug 4, 25$5.24Aug 6, 25$5.73Aug 11, 25$5.53Aug 13, 25$6.67Aug 15, 25$7.26Aug 19, 25$6.57Aug 21, 25$6.85Aug 25, 25$6.74Aug 27, 25$6.46Aug 29, 25$6.16Sep 3, 25$6.47Sep 5, 25$7.27Sep 9, 25$6.97Sep 11, 25$7.07Sep 16, 25$6.69Sep 18, 25$7.10Sep 22, 25$7.40Sep 24, 25$8.44Sep 26, 25$8.39Sep 30, 25$8.69Oct 2, 25$8.67Oct 6, 25$8.40Oct 8, 25$9.66Oct 10, 25$8.90Oct 14, 25$9.97Oct 16, 25$10.09Oct 21, 25$11.24Oct 23, 25$10.00Oct 27, 25$12.27Oct 29, 25$11.41Oct 31, 25$11.50Nov 4, 25$10.75Nov 6, 25$10.92Nov 10, 25$10.17Nov 12, 25$10.97Nov 14, 25$10.79Nov 18, 25$10.09Nov 20, 25$10.34Nov 25, 25$10.68Nov 28, 25$11.66Dec 2, 25$10.13Dec 4, 25$11.19Dec 8, 25$11.08Dec 10, 25$10.83Dec 12, 25$10.84Dec 16, 25$11.52Dec 18, 25$8.69Dec 22, 25$8.71Dec 24, 25$8.10Dec 29, 25$7.68Jan 2, 26$7.32Jan 6, 26$7.19Jan 8, 26$7.30Jan 12, 26$7.50Jan 14, 26$8.76Jan 16, 26$7.55Jan 21, 26$7.69Jan 23, 26$7.96Jan 27, 26$8.49Jan 29, 26$8.97Feb 2, 26$9.15Feb 4, 26$9.29Feb 9, 26$9.08Feb 11, 26$9.25Feb 13, 26$9.35Feb 18, 26$9.17Feb 20, 26$9.02Feb 24, 26$10.07Feb 26, 26$9.66Mar 2, 26$9.33Mar 4, 26$8.93Mar 6, 26$8.48Mar 10, 26$8.87Mar 12, 26$8.45Mar 17, 26$8.61Mar 19, 26$8.98Mar 23, 26$9.23Mar 25, 26$9.88Mar 27, 26$9.33Mar 31, 26$9.31Apr 2, 26$9.48Apr 7, 26$10.24Apr 9, 26$9.84Apr 13, 26$10.04Apr 15, 26$9.77Apr 17, 26$10.49Apr 22, 26$9.80Apr 24, 26$9.40Apr 28, 26$9.42Apr 30, 26$8.87May 4, 26$9.44May 6, 26$10.42May 8, 26$10.14May 12, 26$10.34May 14, 26$9.81May 18, 26$8.37May 20, 26$8.47May 22, 26$8.60May 28, 26$8.97Jun 1, 26$9.71Jun 3, 26$9.53Jun 5, 26$8.64Jun 9, 26$9.23Jun 11, 26$8.84Jun 15, 26$9.22Jun 17, 26$9.42Jun 22, 26$10.42Jun 24, 26$11.62Jun 26, 26$11.60Jul 2, 26$12.95
$3.9552-week range$13.30
Loading valuation history…

Fundamentals

Key fundamentals

$506.6M

Market cap

230194.6%

Revenue growth (YoY)

91.0%

Gross margin

-$109.6M

Free cash flow (USD)

-$381.2M

Net debt

Net cash position

7.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$5.8MFY 2018$14.1MFY 2019$7.0MFY 2020$13.6MFY 2021$18.0MFY 2022$3.1MFY 2023$20.7MFY 2024$37.0KFY 2025$85.2M
$5.8M$85.2M

Free cash flow by year

2017 → 2025

FY 2017$7.7MFY 2018$-16.7MFY 2019$-39.9MFY 2020$-51.9MFY 2021$-78.2MFY 2022$-98.2MFY 2023$-78.6MFY 2024$-138.4MFY 2025$-109.6M
$7.7M-$109.6M

Gross margin by year

2021 → 2025

FY 2021-240.2%FY 2022-2464.8%FY 2023-368.5%FY 2024100.0%FY 202591.0%
-240.2%91.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventDebt Financing AgreementJun 29, 2026Filing
  • Insider sellInsider Sell $118KBizily Scott · Chief Legal Officer · $117.7KJun 25, 2026Filing
  • Insider sellInsider Sell $1.2M · 10b5-1 PlanKirn David · Director, See Remarks · $1.2MJun 23, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • FinancingSecurities RegistrationMay 7, 2026Filing

Questions

Frequently asked questions

What is 4D Molecular Therapeutics, Inc.'s market cap?

4D Molecular Therapeutics, Inc. (FDMT) has a market capitalization of $506.6M.

What is FDMT's P/E ratio?

A meaningful P/E ratio is not available for FDMT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is FDMT's price-to-book (P/B) ratio?

FDMT trades at 1.00 times book value per share.

Are insiders buying FDMT stock?

SEC Form 4 filings show no open-market insider buys at 4D Molecular Therapeutics, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

$499.1M

AUTL

Autolus Therapeutics plc

$492.4M

XOMA

XOMA Royalty Corp.

$523.3M

ALLO

Allogene Therapeutics, Inc.

$524.6M

PRTA

Prothena Corporation plc

$528.8M

EBS

Emergent BioSolutions Inc.

$478.8M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.